Antiepileptic DrugsRené H. Levy The thoroughly revised, updated Fifth Edition of this classic is the m ost comprehensive, current, and authoritative reference on all anticon vulsants available today. This edition features detailed profiles of n ewer drugs--including levetiracetam, oxcarbazepine, tiagabine, topiram ate, and zonisamide--and new chapters on use of antiepileptic drugs in children and during pregnancy. Drugs are covered in alphabetical ord er and in an easy-to-follow format: mechanisms of action; chemistry, b iotransformation, and pharmacokinetics; interactions; clinical efficac y and use; and adverse effects. Coverage of clinical use includes none pileptic and psychiatric disorders where appropriate. This edition has been trimmed to manageable size by shortening chapters on older, less frequently used drugs. |
Contents
vulsant Screening Project Technology Development cal Neuropharmacology St Vincents Hospital Victoria | 36 |
Roger J Porter MD Vice President Clinical Pharmacol Bernd Schmidt MD PhD Head Department of Neurol | 49 |
Adverse Effects 528 70 Methsuximide 665 | 72 |
Drug Interactions 801 92 Chemistry Biotransformation | 85 |
Barbara LeDuc PhD Massachusetts College of Pharmacy rology University of Washington and Director | 96 |
J Steven Leeder PharmD PhD Associate Professor | 102 |
Michel Baulac MD Hôpital de la Salpetriere Bat P Cas gram Department of Psychiatry University Hospitals of Cleveland Cleveland Ohio | 119 |
Contributing Authors xi 12 Antiepileptic Drug Use in Women | 132 |
Chemistry Biotransformation Pharmacokinetics Michael J McLean | 459 |
Clinical Use 340 Meir Bialer | 466 |
Adverse Effects 354 | 476 |
LAMOTRIGINE 361 | 487 |
Chemistry Biotransformation and Richard W Olsen | 496 |
Interactions with Other Drugs 380 Gail D Anderson | 504 |
Clinical Efficacy and Use in Epilepsy 389 J Steven Leeder | 514 |
Adverse Effects 408 Disorders | 522 |
Epilepsy in the Elderly | 149 |
GENERAL PRINCIPLES 1 | 159 |
Principles of Antiepileptic Drug Action 3 Brian K Alldredge | 169 |
Discovery and Preclinical Development | 179 |
Gail D Anderson and John W Miller | 206 |
19 Adverse Effects | 215 |
Regulatory Perspective 66 | 227 |
Robert L Macdonald | 236 |
Combination Therapy and Drug Interactions 96 Edoardo Spina | 247 |
Laboratory Monitoring of Antiepileptic Drugs 103 Colleen J Wurden and René H Levy | 262 |
Use of Antiepileptic Drugs in Children 119 Disorders | 273 |
Marc A Dichter MD Department of Neurology Uni son Institute of Medicine and Clinical Professor of Psy | 349 |
R Eugene Ramsay MD Professor of Neurology and Psy | 354 |
Randall MA PhD Head of Neurophysiology | 363 |
Linda J Stephen MBChB MRCGP Honorary Clinical Karen S Wilcox PhD Research Assistant Professor | 389 |
Mervyn J Eadie MD PhD Emeritus Professor Depart | 403 |
Alan Richens MD PhD Emeritus Professor of Pharma cine University Hospitals of Cleveland Cleveland | 408 |
278 | 419 |
Adverse Effects 285 Doru Georg Margineanu and Henrik Klitgaard | 428 |
Charles P Taylor 44 Mechanisms of Action | 451 |
Methylphenobarbital | 541 |
William R Garnett PharmD Professor of Pharmacy and ment of Neurology University of Medicine and Den | 551 |
K Wayne Riggs PhD Professor Faculty of Pharmaceuti Seattle Washington | 652 |
William J Giardina PhD Associate Research Fellow Washington DC | 675 |
PHENYTOIN AND OTHER William J Giardina | 681 |
Mechanisms of Action 551 Kenneth W Sommerville and Stephen D Collins | 691 |
Chemistry and Biotransformation 565 Kenneth W Sommerville | 698 |
Interactions with Other Drugs 581 Reetta Kälviäinen | 705 |
Clinical Efficacy and Use in Epilepsy 591 Kenneth W Sommerville | 711 |
600 | 719 |
Fosphenytoin 611 Dennis R Doose and Anthony J Streeter | 735 |
Primidone 621 | 753 |
Pharmacokinetics and Drug Interactions 646 83 Mechanisms of Action | 767 |
Clinical Efficacy and Use in Epilepsy 652 84 Chemistry Biotransformation | 780 |
Clinical Efficacy and Use in Psychiatric Disorders 95 Adverse Effects 892 | 828 |
Adverse Effects | 837 |
Pregabalin | 901 |
ZONISAMIDE 865 98 Drugs in Early Clinical Development | 913 |
| 963 | |
Common terms and phrases
absence seizures action activity add-on administration adults adverse effects anticonvulsant antiepileptic drugs barbiturates benzodiazepine brain calcium carba carbamazepine clearance Clin Pharmacol clinical trials clobazam clonazepam compared decrease diazepam disorder dosage dose double-blind efficacy elderly enzyme Epilepsy Res epileptic patients epoxide evaluation felbamate GABA GABAA receptor gabapentin GABAR half-life hepatic human increased induced inhibition intravenous lamotrigine levels levetiracetam liver lorazepam mazepine metabolism metabolite mg/day mg/kg midazolam monitoring monotherapy myoclonic Neurology neurons oral oxcarbazepine partial seizures patients receiving patients with epilepsy pediatric Perucca pharmacokinetics phenobarbital phenytoin placebo placebo-controlled plasma concentrations potential protein binding randomized rectal reduced refractory renal reported seizure control seizure free seizure frequency seizure types serum side effects sodium channels sodium valproate status epilepticus subunit syndrome therapeutic therapy tion tolerability tonic-clonic seizures topiramate toxicity treated treatment valproic acid vigabatrin vitro µg/mL µmol/L